Sivia Capital Partners LLC Purchases 3,419 Shares of IQVIA Holdings Inc. $IQV

Sivia Capital Partners LLC increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 89.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,235 shares of the medical research company’s stock after purchasing an additional 3,419 shares during the period. Sivia Capital Partners LLC’s holdings in IQVIA were worth $1,631,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of IQV. Ameliora Wealth Management Ltd. bought a new stake in shares of IQVIA during the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. raised its position in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the period. International Assets Investment Management LLC bought a new stake in shares of IQVIA during the 4th quarter valued at $27,000. Westside Investment Management Inc. grew its stake in IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new position in IQVIA during the third quarter valued at $30,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQV stock opened at $182.12 on Thursday. IQVIA Holdings Inc. has a 52 week low of $143.00 and a 52 week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a fifty day simple moving average of $171.35 and a two-hundred day simple moving average of $195.26. The firm has a market capitalization of $30.40 billion, a P/E ratio of 22.57, a price-to-earnings-growth ratio of 1.73 and a beta of 1.21.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the business earned $2.70 earnings per share. IQVIA’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.58 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a stock buyback plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Mizuho set a $215.00 target price on shares of IQVIA in a research note on Monday, February 23rd. Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price for the company in a research note on Friday, March 6th. Citigroup cut their target price on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Finally, Jefferies Financial Group cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.